Sinopharm Says Second-Generation Vaccine Approved for Trial
(Bloomberg) -- China National Pharmaceutical Group Co. said its second-generation recombinant protein Covid-19 vaccine has received approval from Beijing for clinical trials.
Better known as Sinopharm, the state-owned enterprise's vaccine-developing unit, China National Biotec Group, announced the news on its WeChat account on Sunday. The improved vaccine has already been approved by the United Arab Emirates as a booster shot and enhances immune response to the coronavirus, the company said in December.
China is currently grappling with its worst infection outbreak since the early days of the pandemic, reporting more than 13,000 new Covid-19 cases on Sunday. Vice Premier Sun Chunlan arrived in the country's virus hotspot of Shanghai to oversee prevention efforts, as she ordered officials to curtail the outbreak “as soon as possible,” according to Xinhua. Cases in the financial hub exceeded 8,000 on Saturday including 7,788 asymptomatic infections. Shanghai will start a new round of mass testing on Monday, authorities said.
©2022 Bloomberg L.P.
With assistance from Bloomberg
-
Talking Points This Week: Tech Nerves, FII Buying, And A Faraway Banking Shock
The global markets are not shining this Diwali. The exception in the large markets is, India.
-
Midterm Rally Lasted A Day. The Hard Reality Of A Divided US May Last Two Years | Opinion
Between a contested AI boom, a debt ceiling that arrives in 2027 and a president with every incentive to act alone, the next two years may prove more volatile than the first day's rally suggests.
-
Blue Wave Will Derail the AI Trade but Won't Dismantle the AI Era | Unhedged Position
The Democrats' sweep of the US Congress will see politics collide with economic forces both over the long and short term.
-
It's Time To Take The GST Council's Bet On Trust Global
Payment records can prove India's services exports, and clear, proportionate rules can bring foreign digital sellers into the tax net.
-
Opinion | India at 38: From Innovation Overperformer to Innovation Powerhouse
India now has 453 VC-backed deep science startups, 18 of them late-stage, after 117 percent growth since 2020. Laurus Labs, at USD 9.3 billion, is the most valuable deep science company in any middle-income economy outside China.
-
Navigating Energy Crossroads: S Jaishankar's Call For Diversified Supply Chains At G20 Ministerial Meeting
As geopolitical fault lines continue to test maritime trade routes and commodity flows, Jaishankar's message remains pertinent: true economic resilience requires open markets, protected transit lines, and a genuine commitment to multilateral cooperation rather than coercion.
-
Indians Are Travelling, But Not Every Journey Is A Holiday | The Week In Whys
Pilgrims, patients and working women are the real travellers, and the system hasn't quite caught up with them.
-
Getting To Work Costs Women More | The Reason Why
It is not just about women paying more than men. It is about women paying much more in cities than in villages.
-
AI Bias In Investing Cannot Be Eliminated, But It Can Be Governed
Framing is a particularly important example as identical financial information presented in terms of gains rather than losses can lead an LLM to reach a different assessment.
